Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
NOT YET RECRUITING
NCT07156500
PHASE3

A Phase 3 Study of HS-20094 in Patients With T2DM Inadequately Controlled With Diet and Exercise Alone

Sponsor: Jiangsu Hansoh Pharmaceutical Co., Ltd.

View on ClinicalTrials.gov

Summary

This is a multicenter, randomized, double-blind, placebo-controlled Phase III clinical study to evaluate the efficacy and safety of HS-20094 injection in subjects with type 2 diabetes who have inadequate glycemic control with diet and exercise alone. The primary objective of this study is to evaluate the effectiveness of HS-20094 compared to placebo in controlling blood glucose levels after 44 weeks and 52 weeks treatment.

Official title: A Multicenter, Randomized, Double-Blind, Placebo- Parallel Controlled, Phase III Study to Evaluate the Efficacy and Safety of HS-20094 Injection in Subjects With Type 2 Diabetes, Inadequately Controlled With Diet and Exercise Alone

Key Details

Gender

All

Age Range

18 Years - Any

Study Type

INTERVENTIONAL

Enrollment

204

Start Date

2025-09-30

Completion Date

2027-05-30

Last Updated

2025-09-05

Healthy Volunteers

No

Conditions

Interventions

DRUG

HS-20094 Injection

HS-20094 injected subcutaneously once weekly

DRUG

HS-20094 Placebo Injection

HS-20094 Placebo injected subcutaneously once weekly

DRUG

HS-20094 Injection

HS-20094 injected subcutaneously once weekly

DRUG

HS-20094 Placebo Injection

HS-20094 Placebo injected subcutaneously once weekly

Locations (1)

Beijing Hospital

Beijing, Beijing Municipality, China